Home » Stocks » Arbutus Biopharma

Arbutus Biopharma Corporation (ABUS)

Stock Price: $3.66 USD -0.14 (-3.68%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $3.73 +0.07 (1.91%) Aug 10, 7:59 PM

Stock Price Chart

Key Info

Market Cap 260.80M
Revenue (ttm) 7.68M
Net Income (ttm) -135.11M
Shares Out 68.96M
EPS (ttm) -2.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $3.66
Previous Close $3.80
Change ($) -0.14
Change (%) -3.68%
Day's Open 3.72
Day's Range 3.61 - 3.76
Day's Volume 2,514,705
52-Week Range 0.82 - 9.02

More Stats

Market Cap 260.80M
Enterprise Value 181.28M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 68.96M
Float 38.73M
EPS (basic) -2.46
EPS (diluted) -2.32
FCF / Share -0.88
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 641,197
Short Ratio 0.88
Short % of Float 1.49%
Beta 3.25
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 33.94
PB Ratio 2.44
Revenue 7.68M
Operating Income -130.55M
Net Income -135.11M
Free Cash Flow -61.46M
Net Cash 79.52M
Net Cash / Share 1.12
Gross Margin -671.40%
Operating Margin -1,698.96%
Profit Margin -1,909.80%
FCF Margin -799.83%
ROA -24.34%
ROE -117.49%
ROIC -268.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.80*
(58.47% upside)
Low
4.00
Current: $3.66
High
8.00
Target: 5.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue6.015.9510.701.4923.2814.9515.4714.1116.81
Revenue Growth1.11%-44.44%617.64%-93.59%55.66%-3.31%9.64%-16.1%-
Gross Profit6.015.9510.701.4923.2814.9515.4714.1116.81
Operating Income-144-89.78-111-492-104-33.43-12.15-12.95-10.69
Net Income-154-57.06-84.41-384-62.72-38.84-14.0629.61-10.08
Shares Outstanding57.0955.3054.7253.0745.4621.6015.3013.7311.32
Earnings Per Share-2.89-1.21-1.56-7.24-1.38-1.80-0.922.07-0.89
Operating Cash Flow-71.01-67.87-48.64-57.89-56.38-12.42-6.7432.91-7.83
Capital Expenditures-0.58-1.11-7.26-3.97-2.29-0.98-0.73-0.01-0.06
Free Cash Flow-71.58-68.98-55.90-61.86-58.67-13.40-7.4632.90-7.89
Cash & Equivalents90.8312512613118111268.7247.020.00
Total Debt3.02-12.0012.00-----
Net Cash / Debt87.8212511411918111268.7247.020.00
Assets10622823727671211871.7252.60-
Liabilities32.7927.6754.6972.9116530.1412.5211.68-
Book Value72.7420018220354888.0459.1940.92-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Arbutus Biopharma Corporation
Country United States
Employees 78
CEO William H. Collier

Stock Information

Ticker Symbol ABUS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ABUS

Description

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.